Molecular serum and urine marker repertoire supporting clinical research on joint diseases

Best Practice and Research: Clinical Rheumatology

Volumn 25, Issue 6, 2011, Pages 859-872

  Qvist, Per ^a   Bay Jensen, Anne Christine ^a   Christiansen, Claus ^a   Sondergaard, Bodil Cecilie ^a   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Arthritis; Biochemical markers; Joint diseases; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

AGGRECAN; AGGRECAN 846; ALANYLARGINYLGLYCYLSERYLVALINE; BIOCHEMICAL MARKER; C TERMINAL COLLAGEN TYPE II TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; CARTILAGE OLIGOMERIC MATRIX PROTEIN; GLUCOSYLGALACTOSYLPYRIDINOLINE; HYALURONIC ACID; MOLECULAR MARKER; TYPE II COLLAGEN NEOEPITOPE; TYPE IIA PROCOLLAGEN AMINO TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG;

ARTHROPATHY; BLOOD LEVEL; CARTILAGE; CLASSIFICATION; CLINICAL RESEARCH; DIAGNOSTIC VALUE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; URINE LEVEL;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CARTILAGE, ARTICULAR; HUMANS; JOINT DISEASES;

EID: 84856003066     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2011.11.004     Document Type: Review

References (114)

1. P.S. Emrani, J.N. Katz, C.L. Kessler, W.M. Reichmann, E.A. Wright, and T.E. McAlindon Joint space narrowing and Kellgren-Lawrence progression in knee osteoarthritis: an analytic literature synthesis Osteoarthritis and Cartilage 16 8 2008 873 882
2. T. Buclin, R.M. Cosma, P. Burckhardt, M. Azria, and M. Attinger Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers Journal of Bone and Mineral Research 17 8 2002 1478 1485 (Pubitemid 34803831)
3. R. Eastell, and R.A. Hannon Biomarkers of bone health and osteoporosis risk The Proceedings of the Nutrition Society 67 2 2008 157 162 (Pubitemid 351543397)
4. D.C. Bauer, D.J. Hunter, S.B. Abramson, M. Attur, M. Corr, and D. Felson Classification of osteoarthritis biomarkers: a proposed approach Osteoarthritis and Cartilage 14 8 2006 723 727 (Pubitemid 43986366)
5. L.H. van Tuyl, A.E. Voskuyl, M. Boers, P. Geusens, R.B. Landewe, and B.A. Dijkmans Baseline RANKL: OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis Annals of the Rheumatic Diseases 69 9 2010 1623 1628
6. L.H. van Tuyl, A.M. Plass, W.F. Lems, A.E. Voskuyl, P.J. Kerstens, and B.A. Dijkmans Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis Rheumatology (Oxford) 47 10 2008 1571 1576
7. L.H. van Tuyl, W.F. Lems, A.E. Voskuyl, P.J. Kerstens, P. Garnero, and B.A. Dijkmans Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial Annals of the Rheumatic Diseases 67 11 2008 1574 1577
8. R.B. Landewe, P. Geusens, H.D. van der, M. Boers, L.S. van der, and P. Garnero Arthritis instantaneously causes collagen type-I and type-II degradation in patients with early rheumatoid arthritis. A longitudinal analysis Arthritis & Rheumatism 54 6 2006 1
9. R. Landewe, P. Geusens, M. Boers, H.D. van der, W. Lems, and K.J. te Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis Arthritis & Rheumatism 50 5 2004 1390 1399 (Pubitemid 38608060)
10. P. Garnero, R. Landewé, M. Boers, A. Verhoeven, S. van der Linden, and S. Christgau Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study Arthritis & Rheumatism 46 11 2002 2847 2856 (Pubitemid 35315875)
11. I. Meulenbelt, M. Kloppenburg, H.M. Kroon, J.J. Houwing-Duistermaat, P. Garnero, and M.P. Hellio Le Graverand Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study Annals of the Rheumatic Diseases 65 3 2006 360 365 (Pubitemid 43268226)
12. K.M. Jordan, H.E. Syddall, P. Garnero, E. Gineyts, E.M. Dennison, and A.A. Sayer Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men Annals of the Rheumatic Diseases 65 7 2006 871 877
13. P. Garnero, B. Mazieres, A. Gueguen, M. Abbal, L. Berdah, and M. Lequesne Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort Journal of Rheumatology 32 4 2005 697 703 (Pubitemid 40524704)
14. V.B. Kraus, T.B. Kepler, T. Stabler, J. Renner, and J. Jordan First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis PLoS One 5 3 2010 e9739
15. O.V. Nemirovskiy, D.R. Dufield, T. Sunyer, P. Aggarwal, D.J. Welsch, and W.R. Mathews Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo Analytical Biochemistry 361 1 2007 93 101 (Pubitemid 46026997)
16. A. Bay-Jensen, J. Wang, I. Byrjalsen, Y. Li, Q. Liu, and D.J. Leeming Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM - increased serum CIIM in subjects with severe radiographic osteoarthritis Journal of Clinical Biochemistry 44 5-6 2011 Apr 423 429
17. A. Bay-Jensen, E. Dam, I. Byrjalsen, T. schubert, P. Vergnaud, and P. Qvist A novel serum biomarker of cartilage destruction, measured in OA and RA patients, is significantly associated with Kellgren-Lawrence score Arthritis & Rheumatism 62 11 2010 Ref Type: Abstract
18. S. Larsson, L.S. Lohmander, and A. Struglics Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study Arthritis Research & Therapy 11 3 2009 R92
19. S. Larsson, M. Englund, A. Struglics, and L.S. Lohmander Association between synovial fluid levels of aggrecan ARGS fragments and radiographic progression in knee osteoarthritis Arthritis Research & Therapy 12 6 2010 R230
20. C.A. Swearingen, J.W. Carpenter, R. Siegel, I.J. Brittain, J. Dotzlaf, and T.B. Durham Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine Osteoarthritis and Cartilage 18 9 2010 1150 1158
21. M. Reijman, J.M. Hazes, S.M. Bierma-Zeinstra, B.W. Koes, S. Christgau, and C. Christiansen A new marker for osteoarthritis: cross-sectional and longitudinal approach Arthritis & Rheumatism 50 8 2004 2471 2478 (Pubitemid 39062707)
22. D.J. Hunter, J. Li, M. LaValley, D.C. Bauer, M. Nevitt, and J. DeGroot Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study Arthritis Research & Therapy 9 5 2007 R108
23. B. Mazieres, P. Garnero, A. Gueguen, M. Abbal, L. Berdah, and M. Lequesne Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort Annals of the Rheumatic Diseases 65 3 2006 354 359 (Pubitemid 43268225)
24. E.B. Dam, I. Byrjalsen, M.A. Karsdal, P. Qvist, and C. Christiansen Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI Osteoarthritis and Cartilage 17 3 2009 384 389
25. D.H. Manicourt, M. Azria, L. Mindeholm, E.J. Thonar, and J.P. Devogelaer Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis Arthritis & Rheumatism 54 10 2006 3205 3211 (Pubitemid 44622091)
26. M.A. Karsdal, I. Byrjalsen, A.C. Bay-Jensen, K. Henriksen, B.J. Riis, and C. Christiansen Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis - the effect of sex, Kellgren-Lawrence (KL) score, Body Mass Index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation BMC Musculoskeletal Disorders 11 2010 125
27. M.A. Karsdal, K. Henriksen, A.C. Bay-Jensen, B. Molloy, M. Arnold, and M.R. John Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials Journal of Clinical Pharmacology 2010
28. P. Garnero, J.-C. Rousseau, and P.D. Delmas Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases Arthritis & Rheumatism 43 2000 953 968 (Pubitemid 30368171)
29. S. Schaller, K. Henriksen, P. Hoegh-Andersen, B.C. Sondergaard, E.U. Sumer, and L.B. Tanko In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay and Drug Development Technology 3 2005 553 580 (Pubitemid 41824373)
30. X. Chevalier, and T. Conrozier Biological markers for osteoarthritis: an update Joint Bone Spine 72 2 2005 106 109 (Pubitemid 41388960)
31. E.U. Sumer, S. Schaller, B.C. Sondergaard, L.B. Tanko, and P. Qvist Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review Biomarkers 11 6 2006 485 506 (Pubitemid 44614822)
32. S. Abramson, and S. Krasnokutsky Biomarkers in osteoarthritis Bulletin of the NYU Hospital for Joint Diseases 64 1-2 2006 77 81 (Pubitemid 44625538)
33. V.B. Kraus Do biochemical markers have a role in osteoarthritis diagnosis and treatment? Best Practice & Research Clinical Rheumatology 20 1 2006 69 80 (Pubitemid 43230464)
34. P. Garnero Use of biochemical markers to study and follow patients with osteoarthritis Current Rheumatology Reports 8 1 2006 37 44 (Pubitemid 44659358)
35. P. Garnero Biochemical markers in osteoarthritis: will they measure up? Nature Clinical Practice Rheumatology 2 3 2006 116 117 (Pubitemid 43771815)
36. J.C. Rousseau, and P.D. Delmas Biological markers in osteoarthritis Nature Clinical Practice Rheumatology 3 6 2007 346 356 (Pubitemid 46864889)
37. Y. Henrotin, S. Addison, V. Kraus, and M. Deberg Type II collagen markers in osteoarthritis: what do they indicate? Current Opinion in Rheumatology 19 5 2007 444 450 (Pubitemid 47344236)
38. P. Qvist, C. Christiansen, M.A. Karsdal, S.H. Madsen, B.C. Sondergaard, and A.C. Bay-Jensen Application of biochemical markers in development of drugs for treatment of osteoarthritis Biomarkers 15 1 2010 1 19
39. C.W. Archer, and P. Francis-West The chondrocyte International Journal of Biochemistry & Cell Biology 35 4 2003 401 404 (Pubitemid 36140061)
40. T. Saxne, and D. Heinegard Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood British Journal of Rheumatology 31 9 1992 583 591
41. J. Ryu, C.A. Towle, and B.V. Treadwell Characterisation of human articular cartilage link proteins from normal and osteoarthritic cartilage Annals of the Rheumatic Diseases 41 2 1982 164 167 (Pubitemid 12158519)
42. A.J. Fosang, H. Stanton, C.B. Little, and L.M. Atley Neoepitopes as biomarkers of cartilage catabolism Inflammation Research 52 7 2003 277 282 (Pubitemid 36836481)
43. E.Y. Zhen, I.J. Brittain, D.A. Laska, P.G. Mitchell, E.U. Sumer, and M.A. Karsdal Characterization of metalloprotease cleavage products of human articular cartilage Arthritis & Rheumatism 58 8 2008 2420 2431
44. F. Behrens, E.L. Kraft, and T.R. Oegema Biochemical changes in articular cartilage after joint immobilization by casting or external fixation Journal of Orthopaedic Research 7 1989 335 343 (Pubitemid 19132851)
45. A. Mamehara, T. Sugimoto, D. Sugiyama, S. Morinobu, G. Tsuji, and S. Kawano Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs The Kobe Journal of Medical Sciences 56 3 2010 E98 107
46. P. Garnero, E. Thompson, T. Woodworth, and J.S. Smolen Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone Arthritis & Rheumatism 62 1 2010 33 43
47. W.P. Maksymowych, R. Landewe, M. Boers, P. Garnero, P. Geusens, and H. El-Gabalawy Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials Journal of Rheumatology 34 3 2007 634 640 (Pubitemid 46364023)
48. S.W. Syversen, G.L. Goll, D. van der Heijde, R. Landewe, B.A. Lie, and S. Odegard Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study Annals of the Rheumatic Diseases 69 2 2010 345 351
49. S. Christgau, and P.A. Cloos Current and future applications of bone turnover markers Clinical Laboratory 49 9-10 2003 439 446 (Pubitemid 37266108)
50. M.A. Karsdal, T. Woodworth, K. Henriksen, W.P. Maksymowych, H. Genant, and P. Vergnaud Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities Arthritis Research & Therapy 13 2 2011 215
51. S. Christgau, P. Garnero, C. Fledelius, C. Moniz, M. Ensig, and E. Gineyts Collagen type II C-telopeptide fragments as an index of cartilage degradation Bone 29 3 2001 209 215 (Pubitemid 32823562)
52. T. Sokka, M.L. Hetland, H. Makinen, H. Kautiainen, K. Horslev-Petersen, and R.K. Luukkainen Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries Arthritis & Rheumatism 58 9 2008 2642 2651
53. G.R. Burmester, G. Ferraccioli, R.M. Flipo, I. Monteagudo-Saez, K. Unnebrink, and S. Kary Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study Arthritis & Rheumatism 59 1 2008 32 41 (Pubitemid 351171876)
54. B. Svensson, A. Boonen, K. Albertsson, H.D. van der, C. Keller, and I. Hafstrom Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial Arthritis & Rheumatism 52 11 2005 3360 3370 (Pubitemid 41612202)
55. M.L. Hetland, K. Stengaard-Pedersen, P. Junker, T. Lottenburger, T. Ellingsen, and L.S. Andersen Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study Arthritis & Rheumatism 54 5 2006 1401 1409
56. M.L. Hetland, K. Stengaard-Pedersen, P. Junker, T. Lottenburger, I. Hansen, and L.S. Andersen Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study Annals of the Rheumatic Diseases 67 6 2008 815 822 (Pubitemid 351829382)
57. M.A. Karsdal, I. Byrjalsen, K. Henriksen, B.J. Riis, E.M. Lau, and M. Arnold The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study Osteoarthritis and Cartilage 18 2 2010 150 159
58. O. Nemirovskiy, W.W. Li, and G. Szekely-Klepser Design and validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide in human urine: application as a biomarker of osteoarthritis Methods in Molecular Biology 641 2010 253 270
59. W.W. Li, O. Nemirovskiy, S. Fountain, M.W. Rodney, and G. Szekely-Klepser Clinical validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide: a biomarker of matrix metalloproteinase activity and osteoarthritis in human urine Analytical Biochemistry 369 1 2007 41 53 (Pubitemid 47313372)
60. M.P. Hellio Le Graverand, K.D. Brandt, S.A. Mazzuca, B.P. Katz, R. Buck, and K.A. Lane Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis Osteoarthritis and Cartilage 14 11 2006 1189 1195 (Pubitemid 44490308)
61. S.M. Verstappen, A.R. Poole, M. Ionescu, L.E. King, M. Abrahamowicz, and D.M. Hofman Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis Arthritis Research & Therapy 8 1 2006 R31
62. W.P. Maksymowych, A.R. Poole, L. Hiebert, A. Webb, M. Ionescu, and T. Lobanok Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis Journal of Rheumatology 32 10 2005 1911 1917 (Pubitemid 41429021)
63. H.C. Chen, S. Shah, T.V. Stabler, Y.J. Li, and V.B. Kraus Biomarkers associated with clinical phenotypes of hand osteoarthritis in a large multigenerational family: the CARRIAGE family study Osteoarthritis and Cartilage 16 9 2008 1054 1059
64. J.C. Rousseau, L.J. Sandell, P.D. Delmas, and P. Garnero Development and clinical application in arthritis of a new immunoassay for serum type IIA procollagen NH2 propeptide Methods in Molecular Medicine 101 2004 25 37
65. J.-C. Rousseau, Y. Zhu, P. Miossec, E. Vignon, L.J. Sandell, and P. Garnero Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis Osteoarthritis and Cartilage 12 6 2004 440 447 (Pubitemid 38696944)
66. M. Sharif, J. Kirwan, N. Charni, L.J. Sandell, C. Whittles, and P. Garnero A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis-association with disease progression Rheumatology (Oxford) 46 6 2007 938 943 (Pubitemid 47062500)
67. D.R. Dufield, O.V. Nemirovskiy, M.G. Jennings, M.D. Tortorella, A.M. Malfait, and W.R. Mathews An immunoaffinity liquid chromatography-tandem mass spectrometry assay for detection of endogenous aggrecan fragments in biological fluids: use as a biomarker for aggrecanase activity and cartilage degradation Analytical Biochemistry 406 2 2010 113 123
68. H. Marotte, E. Gineyts, P. Miossec, and P.D. Delmas Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis Annals of the Rheumatic Diseases 68 7 2009 1197 1200
69. S. Young-Min, T. Cawston, N. Marshall, D. Coady, S. Christgau, and T. Saxne Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers Arthritis & Rheumatism 56 10 2007 3236 3247 (Pubitemid 47585418)
70. V. Vilim, M. Olejarova, S. Machacek, J. Gatterova, V.B. Kraus, and K. Pavelka Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis Osteoarthritis and Cartilage 10 9 2002 707 713 (Pubitemid 34993958)
71. M. Sharif, T. Saxne, L. Shepstone, J.R. Kirwan, C.J. Elson, and D. Heinegard Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint British Journal of Rheumatology 34 4 1995 306 310
72. E. Fex, K. Eberhardt, and T. Saxne Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet British Journal of Rheumatology 36 11 1997 1161 1165
73. C. Georges, H. Vigneron, X. Ayral, V. Listrat, P. Ravaud, and M. Dougados Serum biologic markers as predictors of disease progression in osteoarthritis of the knee Arthritis & Rheumatism 40 3 1997 590 591 (Pubitemid 27123683)
74. S.W. Syversen, E.A. Haavardsholm, P. Boyesen, G.L. Goll, C. Okkenhaug, and P.I. Gaarder Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs Annals of the Rheumatic Diseases 69 5 2010 845 850
75. J.Z. de, M. Munneke, V. Vilim, A.H. Zwinderman, H.M. Kroon, and H.K. Ronday Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis-data from the RAPIT study Rheumatology (Oxford) 47 6 2008 868 871 (Pubitemid 351796375)
76. O. Bruyere, J. Collette, M. Kothari, S. Zaim, D. White, and H. Genant Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study Annals of the Rheumatic Diseases 65 8 2006 1050 1054 (Pubitemid 44133268)
77. O. Bruyere, J.H. Collette, O. Ethgen, L.C. Rovati, G. Giacovelli, and Y.E. Henrotin Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis Journal of Rheumatology 30 5 2003 1043 1050 (Pubitemid 36529629)
78. P. Garnero, E. Hausherr, M.C. Chapuy, C. Marcelli, H. Grandjean, and C. Muller Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study Journal of Bone and Mineral Research 11 10 1996 1531 1538 (Pubitemid 26331009)
79. P. Garnero, P. Dargent-Molina, D. Hans, A.M. Schott, G. Breart, and P.J. Meunier Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study Osteoporosis International 8 6 1998 563 569 (Pubitemid 28566972)
80. E.B. Dam, M. Loog, C. Christiansen, I. Byrjalsen, J. Folkesson, and M. Nielsen Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers Arthritis Research & Therapy 11 4 2009 R115
81. A.F. Christensen, K. Horslev-Petersen, S. Christgau, H.M. Lindegaard, T. Lottenburger, and K. Junker Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides Journal of Rheumatology 37 6 2010 1113 1120
82. M.A. Karsdal, I. Byrjalsen, K. Henriksen, B.J. Riis, and C. Christiansen Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy European Journal of Clinical Pharmacology 66 1 2010 29 37
83. A.F. Christensen, T. Lottenburger, H. Lindegaard, S. Christgau, K. Horslev-Petersen, and P. Junker Differential association of the N-propeptide of collagen IIA (PIIANP) and collagen II C-telopeptide (CTX-II) with synovitis and erosions in early and longstanding rheumatoid arthritis Clinical and Experimental Rheumatology 27 2 2009 307 314
84. J. Hashimoto, P. Garnero, H.D. van der, N. Miyasaka, K. Yamamoto, and S. Kawai A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs Modern Rheumatology 19 3 2009 273 282
85. P. Garnero, W.S. Aronstein, S.B. Cohen, P.G. Conaghan, G.A. Cline, and C. Christiansen Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial Osteoarthritis and Cartilage 16 6 2008 660 666 (Pubitemid 351760798)
86. C.O. Bingham III, J.C. Buckland-Wright, P. Garnero, S.B. Cohen, M. Dougados, and S. Adami Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study Arthritis & Rheumatism 54 11 2006 3494 3507 (Pubitemid 44737161)
87. D. Vosse, R. Landewe, P. Garnero, H.D. van der, L.S. van der, and P. Geusens Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis Rheumatology (Oxford) 47 8 2008 1219 1222 (Pubitemid 352038230)
88. F. Chopin, P. Garnero, H.A. le, F. Debiais, A. Daragon, and C. Roux Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis Annals of the Rheumatic Diseases 67 3 2008 353 357 (Pubitemid 351281270)
89. B. Mazieres, M. Hucher, M. Zaim, and P. Garnero Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study Annals of the Rheumatic Diseases 66 5 2007 639 645 (Pubitemid 46707133)
90. P. Alexandersen, M.A. Karsdal, P. Qvist, J.Y. Reginster, and C. Christiansen Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women Bone 40 1 2007 218 222 (Pubitemid 44848419)
91. G. Zhai, F. Cicuttini, C. Ding, F. Scott, P. Garnero, and G. Jones Correlates of knee pain in younger subjects Clinical Rheumatology 26 1 2007 75 80 (Pubitemid 46020026)
92. P. Garnero, N. Charni, F. Juillet, T. Conrozier, and E. Vignon Increased urinary type II collagen helical (Helix-II) and C-telopeptide (CTX-II) levels are independently associated with a rapidly destructive hip osteoarthritis Annals of the Rheumatic Diseases 65 12 2006 1639 1644 (Pubitemid 44799679)
93. C. Ding, P. Garnero, F. Cicuttini, F. Scott, H. Cooley, and G. Jones Knee cartilage defects: association with early radiographic osteoarthritis, decreased cartilage volume, increased joint surface area and type II collagen breakdown Osteoarthritis and Cartilage 13 3 2005 198 205 (Pubitemid 40277277)
94. Y.Z. Bagger, L.B. Tanko, P. Alexandersen, M.A. Karsdal, M. Olson, and L. Mindeholm Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis Bone 37 3 2005 425 430 (Pubitemid 41160502)
95. N. Charni, F. Juillet, and P. Garnero Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis Arthritis & Rheumatism 52 4 2005 1081 1090 (Pubitemid 40530115)
96. M. Jung, S. Christgau, M. Lukoschek, D. Henriksen, and W. Richter Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis Pathobiology 71 2 2004 70 76 (Pubitemid 38056726)
97. P. Garnero, M. Piperno, E. Gineyts, S. Christgau, P.D. Delmas, and E. Vignon Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage Annals of the Rheumatic Diseases 60 6 2001 619 626 (Pubitemid 32493990)
98. P. Garnero, C. Peterfy, S. Zaim, and M. Schoenharting Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study Arthritis & Rheumatism 52 9 2005 2822 2829 (Pubitemid 41369112)
99. D.H. Manicourt, M. Bevilacqua, V. Righini, J.P. Famaey, and J.P. Devogelaer Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis Drugs in Research & Development 6 5 2005 261 271
100. S.W. Syversen, G.L. Goll, H.D. van der, R. Landewe, P.I. Gaarder, and S. Odegard Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression Journal of Rheumatology 36 2 2009 266 272
101. S.A. Mazzuca, A.R. Poole, K.D. Brandt, B.P. Katz, K.A. Lane, and T. Lobanok Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis Journal of Rheumatology 33 6 2006 1147 1151 (Pubitemid 43825469)
102. J. Cibere, A. Thorne, J.A. Kopec, J. Singer, J. Canvin, and D.B. Robinson Glucosamine sulphate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers Journal of Rheumatology 32 5 2005 896 902 (Pubitemid 40676501)
103. A.R. Poole, M. Ionescu, M.A. Fitzcharles, and R.C. Billinghurst The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases Journal of Immunological Methods 294 1-2 2004 145 153 (Pubitemid 39626599)
104. K.B. King, C.T. Lindsey, T.C. Dunn, M.D. Ries, L.S. Steinbach, and S. Majumdar A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees Magnetic Resonance Imaging 22 8 2004 1117 1123 (Pubitemid 39451892)
105. S.Y. Kong, T.V. Stabler, L.G. Criscione, A.L. Elliott, J.M. Jordan, and V.B. Kraus Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis Arthritis & Rheumatism 54 8 2006 2496 2504 (Pubitemid 44205010)
106. S. Visvanathan, J.C. Marini, J.S. Smolen, E.W. Clair, C. Pritchard, and W. Shergy Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis Journal of Rheumatology 34 7 2007 1465 1474 (Pubitemid 47067980)
107. T.H. Kim, M. Stone, U. Payne, X. Zhang, M. Ionescu, and T. Lobanok Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response Arthritis & Rheumatism 52 3 2005 885 891 (Pubitemid 40365112)
108. I.G. Otterness, E. Weiner, A.C. Swindell, R.O. Zimmerer, M. Ionescu, and A.R. Poole An analysis of 14 molecular markers for monitoring osteoarthritis. Relationship of the markers to clinical end-points Osteoarthritis and Cartilage 9 3 2001 224 231 (Pubitemid 32396378)
109. I.G. Otterness, A.C. Swindell, R.O. Zimmerer, A.R. Poole, M. Ionescu, and E. Weiner An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline Osteoarthritis and Cartilage 8 3 2000 180 185 (Pubitemid 30304185)
110. J.C. Rousseau, E.U. Sumer, G. Hein, B.C. Sondergaard, S. Madsen, and C. Pedersen Patients with rheumatoid arthritis have an altered circulatory aggrecan profile BMC Musculoskeletal Disorders 9 1 2008 74
111. S.Y. Kawashiri, A. Kawakami, Y. Ueki, T. Imazato, N. Iwamoto, and K. Fujikawa Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab Joint Bone Spine 77 5 2010 418 420
112. K. Fujikawa, A. Kawakami, M. Tamai, M. Uetani, S. Takao, and K. Arima High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion Journal of Rheumatology 36 6 2009 1126 1129
113. R.K. Chaganti, A. Kelman, L. Lui, W. Yao, M.K. Javaid, and D. Bauer Change in serum measurements of cartilage oligomeric matrix protein and association with the development and worsening of radiographic hip osteoarthritis Osteoarthritis and Cartilage 16 5 2008 566 571 (Pubitemid 351524699)
114. M. Sharif, R. Granell, J. Johansen, S. Clarke, C. Elson, and J.R. Kirwan Serum cartilage oligomeric matrix protein and other biomarker profiles in tibiofemoral and patellofemoral osteoarthritis of the knee Rheumatology (Oxford) 45 5 2006 522 526